about
Role of HLA Adaptation in HIV EvolutionEpigenetic control of HIV-1 post integration latency: implications for therapyAnimal models in HIV cure researchDynamic models of viral replication and latencyTIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV InfectionUsing animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchUnderstanding HIV latency: the road to an HIV cureNew developments in anti-malarial target candidate and product profilesAn in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patientsTargeted cytotoxic therapy kills persisting HIV infected cells during ARTWhen noise makes music: HIV reactivation with transcriptional noise enhancers.A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionMeasuring reversal of HIV-1 latency ex vivo using cells from infected individualsSimilarity in viral and host promoters couples viral reactivation with host cell migrationThe CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle SanctuaryKaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2.Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Reduced evolutionary rates in HIV-1 reveal extensive latency periods among replicating lineagesDendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytesProgress towards an HIV cure: update from the 2014 International AIDS Society SymposiumExploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Measuring glutathione redox potential of HIV-1-infected macrophages.Expression of the memory marker CD45RO on helper T cells in macaquesHIV-1 transcriptional regulation in the central nervous system and implications for HIV cure researchChoice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cellsDynamics of HIV latency and reactivation in a primary CD4+ T cell model.Screening for noise in gene expression identifies drug synergiesCompartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.CD4 mimetics sensitize HIV-1-infected cells to ADCC.Can HIV Be Cured and Should We Try?Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.The Depsipeptide Romidepsin Reverses HIV-1 Latency In VivoAn evolutionary role for HIV latency in enhancing viral transmission.Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
P2860
Q26772713-87CD4C2B-7C04-430C-A7E5-3C9AB5EE262CQ26781191-635FEF2C-6C77-4D36-A6E9-8F8CAFD8CA13Q26853069-C14101C9-C0F9-4A39-A833-E0AF9175ED40Q26866136-2E7166EF-3E4D-447F-BC0C-3F3C324B8538Q27316403-1A24B3EE-1A39-4893-9A57-D851C11291C6Q28077662-D424DEEE-783B-4EC3-AA4E-433A5E9B9213Q28085296-3F36FE75-5AF4-45D3-B116-A344D496A91AQ28468598-C050B144-AED1-43E4-B093-F71C03605E01Q28538015-B3031C91-94DA-48D3-8EF6-19A5EC9005E7Q28538598-003CE5DC-12BF-4DAD-B32C-173DA2977C4CQ30367371-E6992840-2E23-4622-AFEE-440A9CD5ED35Q30385378-CAF3C817-06FB-43AB-BD42-6354A5139655Q33593633-C034E33C-A0D9-4628-AC1A-FFB374AE8A03Q33620546-80D13659-3361-4BBE-BBDB-720E488C639EQ33627182-FF85A06C-314C-4062-9DA6-0AB42BEBD887Q33640033-AE991A3F-A865-4D14-945D-9BA06E1650F0Q33725916-FBAF1FEA-F583-4165-AEE4-1F4C77C31180Q33742139-A27C07D3-0204-4D40-9710-B4787CB2E903Q33743857-14812ECA-F815-47D4-9A91-647DE8F4405AQ33838633-492B5BBF-CC02-449C-9156-32006BDAFFC5Q34180174-A55A4D8D-2DE3-4301-9CED-B18BA5C28CEAQ34218827-6C63B81D-7557-4B58-B87D-76683F0CB47AQ34362894-566D059D-B78A-4C8A-9A91-86E7CC226E54Q34649701-A583CE3C-023A-4D6F-8AF8-4C3F77352537Q34869380-00B60409-36A6-44DD-A153-D8134246EB03Q34869927-CE593D7A-5D87-4440-BDAE-27D209AA2FB6Q34958392-26A2E925-C990-4ABA-B5B6-7AF57B7F8E01Q34984611-93F0DBCB-8B31-4597-A6B1-84223E7865B7Q35009720-F35DA6D0-6850-4D86-9AD7-74AE57C73B71Q35111879-8F3307DE-01D5-4731-BEC6-F8B4148B13F7Q35176166-F6CE35BF-42F1-4D42-888B-8D0665AB198AQ35182580-59942A1B-84DA-4595-9DBE-DC0324D3F6F8Q35606068-7557BE20-46B2-4E8C-BD94-12D10E6493F8Q35644696-7CD25C79-5778-44AF-80D0-1482BDFEFDB4Q35690470-99F8F6D2-1012-48B5-849D-87A296A9E8E2Q35720063-9A72F45A-6DFD-4163-8623-47CEA44D7C7BQ35778783-E6EF4E4C-2E36-4023-A97C-932DAD31F2B0Q35807225-0B42E98A-A31A-4911-8FAB-90C5AA1F8283Q35819184-D8EEB1BD-E186-463A-994C-E4DEEA02DBEBQ35829282-A2181F89-90A1-4FCF-B958-E83E83FEF671
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
HIV: Shock and kill.
@en
HIV: Shock and kill.
@nl
type
label
HIV: Shock and kill.
@en
HIV: Shock and kill.
@nl
prefLabel
HIV: Shock and kill.
@en
HIV: Shock and kill.
@nl
P2860
P356
P1433
P1476
HIV: Shock and kill.
@en
P2860
P2888
P304
P356
10.1038/487439A
P407
P577
2012-07-25T00:00:00Z
P6179
1050949395